Evidence map›Paper›PMID 40501957›Full record

ArticlebioRxiv : the preprint server for biology2025

Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.

Xuechun Wang, Loan Duong, Yujing Qin, Rossella Parrotta, Paresh Kumar Purohit, Yihao Fang, Guoqiang Liu, Jianping He, Jiling Wen, Yan Liu and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Xuechun WangDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Loan DuongDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Yujing QinDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Rossella ParrottaSchool of Chemical and Biological Sciences, University of Galway, H91 TK33 Galway, Ireland.
Paresh Kumar PurohitDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Yihao FangDepartment of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN 46556, USA.
Guoqiang LiuDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Jianping HeDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Jiling WenDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Yan LiuDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Yuting ZhangDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Junling ZhaoDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Zachary T SchaferDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Xuemin LuDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.
Eva SzegezdiSchool of Chemical and Biological Sciences, University of Galway, H91 TK33 Galway, Ireland.ORCID 0000-0002-5708-3535
Xin LuDepartment of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556, USA.

Funding

Mitophagy-Mediated Cell Death in Mammary TumorigenesisR01CA262439 · NCI · UNIVERSITY OF NOTRE DAME · PI SCHAFER, ZACHARY T. · 2021 to 2025
$2.1M
Converting Cold to Hot Tumor Microenvironment in Prostate Cancer by Targeting Chromatin EffectorR01CA248033 · NCI · UNIVERSITY OF NOTRE DAME · PI LU, XIN · 2020 to 2024
$1.8M
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating NeutrophilsR01CA280097 · NCI · UNIVERSITY OF NOTRE DAME · PI Xin Lu · 2023 to 2026
$1.4M
NCI NIH HHS R01 CA248033NCI NIH HHS R01 CA262439NCI NIH HHS R01 CA280097
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer. Loss of

Indexed as

belzutifanHIF2αrenal cell carcinomasynthetic essentialityTRAILVHL

Identifiers

PMID40501957
PMCPMC12154588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.